US Patent 8,163,306 (Drug Delivery System): Claim Scope, Continuation Risk, and US Landscape
US 8,163,306 is directed to an oral, water-insoluble, polymer-coated tablet core architecture that combines (i) one or more active-ingredient layers with rate-controlling excipients and (ii) one or more swellable layers positioned adjacent to selected coating regions. A defining limitation is that the water-insoluble coating contains passageways penetrating to a swellable layer, and the “preselected portions” of the coating that are in communication with the swellable layer and that have a passageway are removed after contact with an aqueous environment, while the remaining coating portion is not removed. This yields immediate onset release after aqueous contact without substantial delay, with optional pH-dependent polymer outer coatings and optional in-lay swellable layers.
The claims provided below map into a layered mechanism: aqueous ingress through discrete passageways to a swellable layer causes localized coating removal at preselected regions, while other coating regions remain intact to preserve directional control of release.
What does independent claim 1 cover (core claim anatomy)?
1) Core structure with two functional layer classes
Claim 1 requires a core that includes:
2) Water-insoluble polymer coating surrounding the core
The entire core is surrounded by a:
- water insoluble polymer coating
This coating is not monolithic in function. Claim 1 ties particular internal coating regions to particular internal layers.
3) Spatial arrangement: swellable layers adjacent to preselected coating portions
Claim 1 requires that:
- One or more swellable layers is located in immediate vicinity of preselected portions of the coating
- The swellable layers are in communication with those preselected coating portions
- The active ingredient layers are in the vicinity of another portion of the coating
This is a segmentation limitation: swellable-layer-adjacent coating portions are distinct from active-layer-adjacent coating portions.
4) Passageways through preselected coating portions
Claim 1 requires:
- The water-insoluble polymer coating comprises one or more passageways
- Those passageways:
- penetrate to at least one swellable layer
- and are located through the preselected portions of the coating
So passageways are not through the entire coating generally; they are through the preselected regions linked to swellable layers.
5) Post-activation coating-removal rule
Claim 1 imposes the key dynamic limitation:
- The preselected portions of the coating that are:
- in communication with the swellable layer and
- have a passageway
- are removed after contact with an aqueous environment
- while the remaining portion of the coating is not removed
This “selective removal” is the hinge between water-insoluble coating survival and aqueous-triggered localized loss.
6) Functional result implied by claim 1
Even though dependent claim 8 states the “no substantial delay” timing explicitly, claim 1 structurally supports the “fast start” profile by creating a mechanism for early water access to a swellable layer through defined passageways, followed by removal of only the targeted coating region.
How broad is the claim set given the dependent limitations?
Below is a scope map for claims 2 to 10, anchored to claim 1.
Claim 2: impermeability limitation
- Coating is impermeable to the pharmaceutically active ingredient
Impact on scope: Narrows to coatings that block drug permeation prior to aqueous activation. A water-insoluble polymer coating is already recited; claim 2 adds an additional barrier characteristic specifically to drug permeation.
Claim 3: multiple actives allowed
- Active ingredients in any active layers may be the same or different
Impact on scope: Broadens to multicomponent dosing architectures.
Claim 4-7: swellable composition content options
- Claim 4: swellable composition comprises a swelling agent
- Claim 5: swelling agent selected from:
- swellable excipient
- gas generating agent
- mixtures
- Claim 6: swellable composition comprises one or more wicking agents
- Claim 7: swellable composition comprises one or more osmogents
Impact on scope: These options expand the swellable layer formulation choices. The key structural requirements remain: swellable layers separate from active layers; swellable layers adjacent to preselected coating portions; passageways penetrate to swellable layer; preselected coated regions are removed after aqueous contact; remaining coating remains.
Claim 8: immediate release timing
- Active ingredient released without a substantial delay after tablet contacts aqueous environment
Impact on scope: Narrows functional performance. It requires the system to meet a release-start timing profile consistent with “no substantial delay.” This can be used to constrain prior art even if structure exists but performance differs.
Claim 9: optional pH-dependent outer coating
- Further comprising an outer coating including a pH-dependent polymer
Impact on scope: Adds a second coating layer system element as an optional limitation (dependent on claim 1). It narrows only those embodiments that add pH responsiveness.
Claim 10: swellable layer form
- One or more swellable composition layers is in the form of an in-lay
Impact on scope: Further constrains embodiment geometry for in-lay configurations but does not foreclose other shapes if not asserted.
What is the “center of gravity” for novelty and likely enforceability?
The independent claim 1 appears to hinge on three combined constraints that collectively differentiate it from generic coated tablets:
-
Selectively removable preselected coating regions
- preselected regions communicating with swellable layer and having passageways
- removed after aqueous contact
- remaining coating portion not removed
-
Passageways penetrating to swellable layer in the preselected regions
- creates an engineered aqueous communication pathway
-
Segregated layer neighborhood mapping
- swellable layers near one coating region; active layers near another
If a competitor omits any one of these, claim 1 coverage can collapse. If a competitor uses swellable excipients but the coating is fully eroded, or if passageways do not penetrate to a swellable layer, or if coating removal is not localized, that supports non-infringement arguments against claim 1 as written.
Patent landscape: US competitive risk model (claim-to-technology mapping)
Core design elements to track across US patents
For an infringement or freedom-to-operate screen against US 8,163,306’s themes, focus on US patents and applications claiming combinations of:
- Water-insoluble polymer coating on oral solid dosage forms
- Defined passageways/ports/microchannels through the coating
- Swellable layer(s) separated from drug layer(s)
- Localized coating failure or erosion limited to regions adjacent to swellable layers
- Rate controlling excipients in the active layer(s)
- Immediate or rapid onset release after aqueous contact
- Optional additions:
- pH-dependent polymer outer coating
- in-lay swellable configuration
How competitors typically “design around”
The most common design-around avenues against this claim architecture are structural:
- Remove selective removal
- Make the coating erode globally (remaining portion removed) rather than selectively
- Break the communication rule
- Position swellable layer not in immediate vicinity of preselected coating portions
- Eliminate passageways penetrating to swellable layer
- Use different water ingress mechanisms (e.g., fully porous coating, non-penetrating channels, or agents dispersed differently)
- Use swellable layers that are not “separate”
- Blend swellable agent into drug layer rather than maintaining separate swellable layers
- Substitute for rate controlling excipient
- Rely on dissolution/efflux modifiers but remove “rate controlling excipient” from at least one active layer (dependent claim 1 requires it “in at least one active layer”)
- Change timing profile
- Add gating that causes substantial delay before release onset
Where this claim is hardest to avoid
The selective coating removal with passageway-to-swellable penetration is a narrower coupling than generic “swellable controlled release” systems. Many historical osmotic and swellable diffusion systems rely on:
- through-orifice drug release,
- erosion-controlled release,
- or globally water-permeable coatings.
The “only preselected portions removed” with “passageways penetrating to swellable layer” is a precise, litigation-relevant formulation.
Claim charts: what each dependent claim adds to coverage (quick mapping)
| Claim |
Added limitation |
Effect on scope |
| 1 |
Orally administerable system; core with active layers (rate controlling excipient in at least one); separate swellable layers adjacent to preselected coating portions; water-insoluble coating with passageways penetrating to swellable layer; preselected coating portions removed after aqueous contact; remaining coating not removed |
Defines the core novelty center: selective removal + engineered passageways + layer adjacency |
| 2 |
Coating impermeable to active ingredient |
Narrows to barrier coatings; supports early containment |
| 3 |
Active ingredients may be same or different across layers |
Broadens multiactive embodiments |
| 4 |
Swellable composition includes swelling agent |
Locks swellable component class |
| 5 |
Swelling agent can be swellable excipient or gas generating agent |
Expands formulation options; not a structural change |
| 6 |
Swellable composition includes wicking agent(s) |
Adds capillary transport elements |
| 7 |
Swellable composition includes osmogen(s) |
Adds osmotic driving components |
| 8 |
Release without substantial delay on aqueous contact |
Adds timing functional performance limitation |
| 9 |
Outer coating with pH-dependent polymer |
Adds multilayer coating option |
| 10 |
Swellable layer in-lay form |
Adds geometric constraint |
What would be “in-scope” versus “out-of-scope” on a structural basis
In-scope indicators
- A coated tablet where the coating is designed with defined passages (ports/channels) aligned to swellable layers
- Swellable layers are structurally separate from drug layers and placed under or next to preselected coating regions
- After water contact, only the targeted regions around the passageways are removed/eroded, while the rest remains intact
- Active layer includes a rate controlling excipient at least in one layer
- The system produces early onset release consistent with “without substantial delay” (claim 8)
Out-of-scope indicators
- Global coating erosion (remaining coating removed)
- No engineered passageways penetrating to swellable layer
- Swellable agent dispersed in drug layer rather than separate swellable layer(s)
- Swellable layer not in immediate vicinity of coating portions linked to passageways
- No rate controlling excipient in at least one active layer
- Performance that shows substantial delay before release onset (claim 8)
Key business implications
1) High sensitivity to “selective removal” language
In enforcement and licensing, claim 1’s selective removal requirement is the lever. Any competing system that causes total coating loss risks reading outside “remaining portion not removed.”
2) Passageway-to-swellable penetration is a critical infringement axis
If a product has porous coating but no passageways that penetrate to the swellable layer, or if passageways terminate short of the swellable region, that can be decisive.
3) Layer adjacency can matter as much as composition
Even when the same excipients are used, the novelty depends on spatial relationships:
- swellable layer immediate vicinity to preselected coating portions
- drug layers in another coating portion
- passageways in the preselected portions
Key Takeaways
- US 8,163,306 claim 1 centers on an oral coated tablet architecture where only preselected coating regions (those communicating with swellable layers via passageways) are removed after aqueous contact, while the remaining coating is not removed.
- The system requires separate swellable layers and active ingredient layers with at least one active layer containing a rate controlling excipient, plus a water-insoluble polymer coating.
- Dependent claims expand scope through formulation options (swelling agent, gas generating agent, wicking agents, osmogens), add optional pH-dependent outer coating, optionally require in-lay placement of swellable layers, and narrow performance via no substantial delay release.
- For landscape and design-around screening, prioritize patents that claim combinations of engineered passageways through a water-insoluble coating aligned to swellable layer(s) and that specify localized coating failure rather than global erosion.
FAQs
-
What is the single most important limitation in claim 1?
The claim requires selective removal of the preselected coating portions that communicate with the swellable layer and include passageways after aqueous contact, while the remaining portion of the coating is not removed.
-
Does the patent require specific swellable chemistries?
Claim 1 requires swellable layers but does not lock chemistry. Dependent claims add options: swelling agent (swellable excipient and/or gas generating agent), plus wicking agents and osmogens.
-
Is the rate controlling excipient required across all active layers?
Claim 1 requires rate controlling excipient in at least one active ingredient composition layer, not necessarily every layer.
-
What coatings are covered?
The system uses a water-insoluble polymer coating with passageways. Claim 2 further requires impermeability to the active ingredient in embodiments where invoked.
-
How does claim 8 affect enforceability against slower-release designs?
Claim 8 requires release without substantial delay after aqueous contact, which can exclude systems that have a longer lag even if the structural features are present.
References
[1] US Patent No. 8,163,306. “Orally administerable drug delivery system” (claims as provided).
